



## VOTING SLIP FOR ANNUAL GENERAL MEETING OF SHAREHOLDERS

**Company name:** Purple Biotech Ltd., company no. 520031238

**Company address (for submission and delivery of Voting Slips):** 4 Oppenheimer Street, Science Park, Rehovot 6701101, Israel, email: nirl@purple-biotech.com; or fax: +972-153-39311321, Attn.: Nir Livneh, Vice President-Legal Affairs and Secretary

**Meeting date:** Thursday, August 25, 2022, at 4:30 p.m. (Israel time).

**Meeting type:** Annual General Meeting (the “Meeting”).

**Record Date:** Monday, July 25, 2022

### **Shareholder details:**

Shareholder name: \_\_\_\_\_

Israeli identification number: \_\_\_\_\_

For shareholders who do not have an Israeli identification card:

Passport number: \_\_\_\_\_

Country of issue: \_\_\_\_\_

Valid until: \_\_\_\_\_

For shareholders that are corporations:

Corporation number: \_\_\_\_\_

Country of incorporation: \_\_\_\_\_

Is the shareholder a “Principal Shareholder<sup>1</sup>”, “Senior Officer of the Company<sup>2</sup>” or an “Institutional Investor<sup>3</sup>”?  
Yes/No (circle as appropriate)

<sup>1</sup> As defined in Section 1 of the Israel Securities Law, 5728-1968 (the “Securities Law”).

<sup>2</sup> As defined in Section 37(d) of the Securities Law.

<sup>3</sup> As defined in Regulation 1 of the Supervision of Financial Services Regulations (Provident Funds) (Participation of a Management Company at a General Meeting), 5769-2009 as well as a Manager of Mutual Funds as per the meaning in the Mutual Funds Law, 5754-1999.

**MANNER OF VOTING**

(Check or mark “X” clearly in each column in accordance with your voting decision.)

	Matter	Manner of Voting		
		For	Against	Abstain
1.	To approve the election of three directors to serve as first class directors, each for a three-year term until the annual general meeting to be held in 2025, and until their respective successors are duly elected and qualified, on the terms set forth in the Proxy Statement:	X		
1(a).	Dr. Eric Rowinsky			
1(b).	Ido Agmon			
1(c).	Robert Gagnon			
2.	To approve the grant of equity-based awards to each of the members of the Board of Directors of the Company.			
3.	To approve the terms of engagement of Mr. Gil Efron as the Company’s new Chief Executive Officer.			
4(a).	To approve the terms of engagement of Mr. Isaac Israel, a director, for service as an advisor to the Company.			
4(b).	To approve the payment to Mr. Isaac Israel of the discretionary portion of the 2020 and 2021 annual bonuses for his former service as the Company’s Chief Executive Officer.			
5.	To approve the payment to Dr. Eric Rowinsky, the Chairman of the Company’s Board of Directors, of an additional fee for service as Chairman of the Company’s Medical and Clinical Committee.			

Do you have a “personal interest” (within the meaning of the Israel Companies Law, 5799 – 1999, and as described in the Proxy Statement for the Meeting) in Proposal 3 or Proposal 4(b) (check or mark “X” clearly in the applicable column)? **Votes cast on Proposal 3 and Proposal 4(b) will not be counted, unless “yes” or “no” has been specified as to whether you have a “personal interest” with respect to such proposal.**

		YES	NO
6.	The undersigned has a personal interest in Proposal 3		
7.	The undersigned has a personal interest in Proposal 4(b)		

\_\_\_\_\_ Date

\_\_\_\_\_ Signature

**For shareholders holding shares through a member of the Tel Aviv Stock Exchange, this Voting Slip is only valid when accompanied by a certification of ownership, in accordance with the Israeli Companies Regulations (Proof of Ownership of Shares for Voting at General Meeting) of 2000. For shareholders registered in the Company’s shareholder registry, this Voting Slip will only be valid when accompanied by a photocopy of a government-issued photograph identification (e.g., passport, identification card or certificate of incorporation (as the case may be)).**